Emerging target-based paradigms to prevent and treat migraine

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 78-85

  Silberstein, S D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; CALCITONIN GENE RELATED PEPTIDE; ELETRIPTAN; ERGOT DERIVATIVE; FROVATRIPTAN; NARATRIPTAN; PLASMA PROTEIN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUBSTANCE P; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ANALGESIA; ARTICLE; BASILAR TYPE MIGRAINE; BRAIN BLOOD VESSEL; BRAIN STEM; CHOLINERGIC TRANSMISSION; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG EFFICACY; HEMIPLEGIC MIGRAINE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER FAILURE; MENINX; MIGRAINE; MIGRAINE AURA; NEUROGENIC INFLAMMATION; NEUROMODULATION; PATHOPHYSIOLOGY; PLASMA PROTEIN EXTRAVASATION; PREGNANCY; PRIORITY JOURNAL; PROTEIN TRANSPORT; SENSORY STIMULATION; SEPSIS; SPREADING CORTICAL DEPRESSION; STATUS MIGRAINOSUS; TRANSFORMED MIGRAINE; TREATMENT RESPONSE; TRIGEMINAL NERVE INJURY; TRIGEMINAL NUCLEUS; VARIANT ANGINA PECTORIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; TRIGEMINAL NERVE;

EID: 84871261412     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.198     Document Type: Article

References (79)

1. Silberstein, S.D., Saper, J.R. & Freitag, F. Migraine: Diagnosis and treatment. In Wolff's Headache and Other Head Pain 7th edn. (eds. Silberstein, S.D., Lipton, R.B. & Dalessio, D.J.) 121-237 (Oxford University Press, New York, 2001).
2. Headache Classification Committee. The International Classification of Headache Disorders 2nd edn. Cephalalgia 24, 1-160 (2004).
3. Stewart, W.F., Lipton, R.B., Celentano, D.D. & Reed, M.L. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267, 64-69 (1992).
4. Russell, M.B. & Olesen, J. A nosographic analysis of the migraine aura in a general population. Brain 119 (Pt 2), 355-361 (1996).
5. Stewart, W.F., Shechter, A. & Lipton, R.B. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 44, S24-S39 (1994).
6. Silberstein, S.D. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 35, 387-396 (1995).
7. Y oung, W.B., Peres, M.F. & Rozen, T.D. Modular headache theory. Cephalalgia 21, 842-849 (2001).
8. Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742-746 (2006).
9. Goadsby, P.J., Lipton, R.B. & Ferrari, M.D. Migraine-current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
10. Leao, A.A.P. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
11. Olesen, J. et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol. 28, 791-798 (1990).
12. Dimitriadou, V., Buzzi, M.G., Theoharides, T.C. & Moskowitz, M.A. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48, 187-203 (1992).
13. Kandere-Grzybowska, K. et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res. 980, 213-220 (2003).
14. Silberstein, S.D. Migraine. Lancet 363, 381-391 (2004).
15. Lipton, R.B. & Silberstein, S.D. Why study the comorbidity of migraine? Neurology 44, S4-S5 (1994).
16. Lipton, R.B., Cady, R.K., O'Quinn, S., Hall, C.B. & Stewart, W.F. Sumatriptan treats the full spectrum of headache in individuals with disabling IHS migraine. Headache 40, 783-791 (1999).
17. Matchar, D.B. et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Neurology (2000).
18. Y oung, W.B., Mannix, L., Adelman, J.U. & Shechter, A.L. Cardiac risk factors and the use of triptans: A survey study. Headache 40, 587-591 (2000).
19. Hoyer, D. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157-203 (1994).
20. Hartig, P.R., Hoyer, D., Humphrey, P.P. & Martin, G.R. Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes. Trends Pharmacol. Sci. 17, 103-105 (1996).
21. Longmore, J. et al. Differential distribution of 5HT1D- and 5HT1Bimmunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs. Cephalalgia 17, 833-842 (1997).
22. Levy, D., Jakubowski, M. & Burstein, R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl. Acad. Sci. USA 101, 4274-4279 (2004).
23. Ferrari, M.D. & Saxena, P.R. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. 14, 129-133 (1993).
24. Humphrey, P.P. & Feniuk, W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci. 12, 444-446 (1991).
25. Lipton, R.B. et al. Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study. Headache 40, 783-791 (2000).
26. Silberstein, S.D., Freitag, F.G. & Bigal, M.E. Migraine treatment. In Wolff's Headache and Other Head Pain 8th edn. (eds. Silberstein, S.D., Lipton, R.B., Dodick, D.W.) 177-292 (Oxford University Press, New York, 2008).
27. Burstein, R., Collins, B., Bajwa, Z. & Jakubowski, M. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: Clinical and preclinical evidence [abstr.]. Headache 42, 390-391 (2002).
28. Cady, R.K. et al. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin. Ther. 22, 1035-1048 (2000).
29. Adham, N. et al. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: A comparison of the pharmacological profile to the human species homolog. Neuropharmacology 36, 569-576 (1997).
30. Nelson, D.L. et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30, 1159-1169 (2010).
31. Farkkila, M. et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 11, 405-413 (2012).
32. Goadsby, P.J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193-196 (1988).
33. Goadsby, P.J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of man. Ann. Neurol. 23, 193-196 (1988).
34. Goadsby, P.J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183-187 (1990).
35. Goldstein, D.J., Wang, O., Saper, J.R., Stoltz, R., Silberstein, S.D. & Mathew, N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study. Cephalalgia 17, 785-790 (1997).
36. Diener, H.C. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In Proceedings of the VIth International Headache Seminar (eds. Olesen, J. and Tfelt-Hansen, P.) (Lippincott-Raven, New York, 1996).
37. Norman, B., Panebianco, D. & Block, G.A. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 18, 407 (1998).
38. Amara, S.G., Arriza, J.L., Leff, S.E., Swanson, L.W., Evans, R.M. & Rosenfeld, M.G. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229, 1094-1097 (1985).
39. Poyner, D.R. et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54, 233-246 (2002).
40. Arulmani, U., Maassenvandenbrink, A., Villalon, C.M. & Saxena, P.R. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur. J. Pharmacol. 500, 315-330 (2004).
41. Olesen, J. et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110 (2004).
42. Ho, T.W. et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70, 1304-1312 (2008).
43. Ho, T.W. et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, paralleltreatment trial. Lancet 372, 2115-2123 (2008).
44. Connor, K.M. et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73, 970-977 (2009).
45. Tfelt-Hansen, P. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache 51, 118-123 (2011).
46. Burgey, C.S. et al. Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines. Bioorg. Med. Chem. Lett. 19, 6368-6372 (2009).
47. Diener, H.C., Barbanti, P., Dahlof, C., Reuter, U., Habeck, J. & Podhorna, J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia 31, 573-584 (2011).
48. Luo, G. et al. Discovery of BMS-846372, a potent and orally active human CGRP receptor agonist for the treatment of migraine. Med. Chem. Lett. 3, 337-341 (2012).
49. Olesen, J., Iversen, H.K. & Thomsen, L.L. Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain. Neuroreport 4, 1027-1030 (1993).
50. Ferrari, M.D., Odink, J., Tapparelli, C., Van Kempen, G.M., Pennings, E.J. & Bruyn, G.W. Serotonin metabolism in migraine. Neurology 39, 1239-1242 (1989).
51. Dawson, T.M., Dawson, V.L. & Snyder, S.H. A novel neuronal messenger molecule in brain: The free radical, nitric oxide. Ann. Neurol. 32, 297-311 (1992).
52. Ladecola, C. Regulation of the cerebral microcirculation during neural activity: Is nitric oxide the missing link? TiPS 16, 206-214 (1993).
53. Lassen, L.H., Ashina, M., Christiansen, I., Ulrich, V. & Olesen, J. Nitric oxide synthase inhibition in migraine. Lancet 349, 401-402 (1997).
54. Alderton, W.K. et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 145, 301-312 (2005).
55. De Alba, J., Clayton, N.M., Collins, S.D., Colthup, P., Chessell, I. & Knowles, R.G. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain 120, 170-181 (2006).
56. Palmer, J.E., Guillard, F.L., Laurijssens, B.E., Wentz, A.L., Dixon, R.M. & Williams, P.M. A selective iNOS inhibitor, in the treatment of migraine [abstr]. Cephalalgia 29, 124 (2009).
57. Hoivik, H.O. et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30, 1458-1467 (2010).
58. Hoye K., Laurijssens B.E., Harnisch L.O., Twomey C.K., Dixon R.M. & Kirkham A. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine [abstr]. Cephalalgia 29,132 (2009).
59. Olesen, J. & Ashina, M. Emerging migraine treatments and drug targets. Trends Pharmacol. Sci. 32, 352-359 (2011).
60. Huang, D.Y., Yu, B.W. & Fan, Q.W. Roles of TRESK, a novel two-pore domain K+channel, in pain pathway and general anesthesia. Neurosci. Bull. 24, 166-172 (2008).
61. Enyedi, P. & Czirjak, G. Molecular background of leak K+ currents: Two-pore domain potassium channels. Physiol. Rev. 90, 559-605 (2010).
62. Liu, C., Au, J.D., Zou, H.L., Cotten, J.F. & Yost, C.S. Potent activation of the human tandem pore domain K channel TRESK with clinical concentrations of volatile anesthetics. Anesth. Analg. 99, 1715-1722, table of contents (2004).
63. Czirjak, G., Toth, Z.E. & Enyedi, P. The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin. J. Biol. Chem. 279, 18550-18558 (2004).
64. Mathie, A. Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors. J. Physiol. (Lond.) 578, 377-385 (2007).
65. Smith, H.S. Calcineurin as a nociceptor modulator. Pain Physician 12, E309-E318 (2009).
66. Lafreniere, R.G. et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat. Med. 16, 1157-1160 (2010).
67. Silberstein, S.D. & Goadsby, P.J. Migraine: Preventive treatment. Cephalalgia 22, 491-512 (2002).
68. Silberstein, S.D., Winner, P.K. & Chmiel, J.J. Migraine preventive medication reduces resource utilization. Headache 43, 171-178 (2003).
69. Ramadan, N.M., Silberstein, S.D., Freitag, F.G., Gilbert, T.T. & Frishberg, B. Evidence-based guidelines of the pharmacological management for prevention of migraine for the primary care provider. Neurology (1999).
70. Silberstein, S.D., Holland, S., Freitag, F., Dodick, D.W., Argoff, C. & Ashman, E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78, 1337-1345 (2012).
71. Diener, H.C. et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 6, 1054-1062 (2007).
72. Zhu, D.X.D. et al. A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicin-induced increase in dermal blood flow in cynomolgus monkeys. American Headache Society 54th Annual Scientific Meeting, Los Angeles, CA, 21 June 2012
73. Liu, H. et al. Immunohistochemical localization of the CLR/RAMP1 receptor complex in the trigeminovascular system of the cynomolgus monkey. Headache 51, 6 (2011).
74. Zeller, J. et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br. J. Pharmacol. 155, 1093-1103 (2008).
75. Wong, H.C. et al. Monoclonal antibody to rat alpha-CGRP: Production, characterization, and in vivo immunoneutralization activity. Hybridoma 12, 93-106 (1993).
76. Ferrari, M.D., Roon, K.I., Lipton, R.B. & Goadsby, P.J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
77. Tfelt-Hansen, P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 18, 532-538 (1998).
78. Thomson, H. Physicians' Desk Reference. 57th edn., (Thomson PDR, Montvale, 2003).
79. Dahlof, C. & Lines, C. Rizatriptan: A new 5-HT1B/1D receptor agonist for the treatment of migraine. Expert Opin. Investig. Drugs 8, 671-685 (1999).